138 related articles for article (PubMed ID: 31324884)
1. Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression.
Xu B; Song B; Lu X; Kim J; Hu M; Zhao JC; Yu J
Cell Res; 2019 Sep; 29(9):773-775. PubMed ID: 31324884
[No Abstract] [Full Text] [Related]
2. Forkhead domain mutations in FOXA1 drive prostate cancer progression.
Gao S; Chen S; Han D; Barrett D; Han W; Ahmed M; Patalano S; Macoska JA; He HH; Cai C
Cell Res; 2019 Sep; 29(9):770-772. PubMed ID: 31324883
[No Abstract] [Full Text] [Related]
3. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T
PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989
[TBL] [Abstract][Full Text] [Related]
5. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
6. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
[TBL] [Abstract][Full Text] [Related]
7. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
[TBL] [Abstract][Full Text] [Related]
8. FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™).
Belikov S; Öberg C; Jääskeläinen T; Rahkama V; Palvimo JJ; Wrange Ö
Mol Cell Endocrinol; 2013 Jan; 365(1):95-107. PubMed ID: 23063623
[TBL] [Abstract][Full Text] [Related]
9. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
Jin HJ; Zhao JC; Wu L; Kim J; Yu J
Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
[TBL] [Abstract][Full Text] [Related]
11. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.
Albayrak G; Konac E; Ugras Dikmen A; Bilen CY
Exp Biol Med (Maywood); 2018 Aug; 243(12):990-994. PubMed ID: 30043639
[TBL] [Abstract][Full Text] [Related]
13. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
14. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin.
Toropainen S; Malinen M; Kaikkonen S; Rytinki M; Jääskeläinen T; Sahu B; Jänne OA; Palvimo JJ
Nucleic Acids Res; 2015 Jan; 43(2):848-61. PubMed ID: 25552417
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-93 Promotes Epithelial-Mesenchymal Transition of Endometrial Carcinoma Cells.
Chen S; Chen X; Sun KX; Xiu YL; Liu BL; Feng MX; Sang XB; Zhao Y
PLoS One; 2016; 11(11):e0165776. PubMed ID: 27829043
[TBL] [Abstract][Full Text] [Related]
16. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially.
Yu X; Gupta A; Wang Y; Suzuki K; Mirosevich J; Orgebin-Crist MC; Matusik RJ
Ann N Y Acad Sci; 2005 Dec; 1061():77-93. PubMed ID: 16467259
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
[TBL] [Abstract][Full Text] [Related]
18. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
Yu P; Duan X; Cheng Y; Liu C; Chen Y; Liu W; Yin B; Wang X; Tao Z
Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]